Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

Dasatinib

Catalog No: tcsc0100

Available Sizes

Size: 100mg

Size: 200mg

Size: 500mg

Size: 1g

Size: 2g

Size: 5g

Size: 10g

Specifications

CAS No:
302962-49-8

Formula:
$C_{22}H_{26}ClN_7O_2S$

Pathway:
Protein Tyrosine Kinase/RTK;Protein Tyrosine Kinase/RTK;Autophagy

Target:
Src;Bcr-Abl;Autophagy

Purity / Grade:
>98%

Solubility:
DMSO : 35.35 mg/mL (72.44 mM; Need ultrasonic and warming)

Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

Alternative Names:
BMS-354825

Observed Molecular Weight:
488.01

Product Description

Dasatinib (BMS-354825) is a dual **Bcr-Abl** and **Src** family tyrosine kinase inhibitor with **IC_{50}**s of 0.6, 0.8, 79 and 37 nM for Abl, Src, c-Kit and c-Kit^{D816V}, respectively.

IC50 & Target: IC50: 0.6 nM/0.8 nM (Abl^{WT}/Src)[1]

IC50: 79 nM/37 nM (c-Kit^{WT}/c-Kit^{D816V})[2]

In Vitro: Dasatinib potently inhibits wild-type Abl kinase and all mutants except T315I over a narrow range (IC_{50}≤1.7 nM). Dasatinib (IC_{50}: 0.8 nM) displays 325-fold greater potency compared with Imatinib against cells expressing wild-type Bcr-Abl in Ba/F3 cells[1].

In Vivo: Daily treatment with Dasatinib (50 mg/kg) is initiated on day 10. Using this approach, a significant inhibition of BCPAP orthotopic tumor growth is observed 6 days after treatment (day 16, P=0.014), which is sustained through days 23 and 29 (P=0.0003), compared with vehicle-treated mice[3]. Metabolism studies of Dasatinib (50 mg/kg) in rat suggested that Dasatinib is the major circulating component, whereas multiple metabolites contributed to the remaining 40-60% of the sample radioactivity at 4 h post dose[4].